A Double-Blind, Randomized, Controlled, Phase 3 Study to Evaluate the Safety and Immunogenicity of CpG 1018/Alum-adjuvanted SCB-2019 in Individuals Aged 18 and Above With Chronic Immune-Mediated Inflammatory Diseases
Latest Information Update: 27 Mar 2023
Price :
$35 *
At a glance
- Drugs SCB 2019 (Primary) ; Hepatitis A vaccine inactivated
- Indications COVID 2019 infections
- Focus Adverse reactions; Registrational
- Sponsors Clover Biopharmaceuticals
- 19 May 2022 Status changed from not yet recruiting to discontinued.
- 24 Aug 2021 New trial record